BF
VYNT

Blankinship & Foster’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Blankinship & Foster’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-41,019
Closed -$277K – 55
2021
Q4 		$277K Hold
41,019
– – 0.11% 49
2021
Q3 		$478K Hold
41,019
– – 0.19% 35
2021
Q2 		$767K Buy
+41,019
New +$765K 0.3% 30

Other funds holding VYNT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
JSC
Jackson Square Capital San Francisco, California $719M AUM 144.18% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

Blankinship & Foster's VYNT Position: Q1 2022 in Review

Blankinship & Foster sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q1 2022, closing a stake of 41,019 shares — an estimated $277K sold.

Blankinship & Foster first reported a position in VYNT in Q2 2021 and held it in 3 quarters. The position peaked at $767K in Q2 2021. 23 funds tracked by Wall St. Rank hold VYNT as of Q1 2022.

  • Blankinship & Foster reported no remaining Vyant Bio, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Blankinship & Foster sold 41,019 Vyant Bio, Inc. Common Stock shares in Q1 2022, an estimated $277K.
  • Blankinship & Foster first reported a position in Vyant Bio, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Blankinship & Foster's Vyant Bio, Inc. Common Stock position peaked at $767K in Q2 2021.
  • 23 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q1 2022.

Based on Blankinship & Foster's 13F filing for Q1 2022, filed 9 May 2022.